You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Ipilimumab and Its Toxicities: A Multidisciplinary Approach
|
|---|---|
| Published in |
Oncologist, June 2013
|
| DOI | 10.1634/theoncologist.2012-0483 |
| Pubmed ID | |
| Authors |
Leslie A. Fecher, Sanjiv S. Agarwala, F. Stephen Hodi, Jeffrey S. Weber |
| Abstract |
The treatment for metastatic melanoma has evolved significantly in the past few years. Ipilimumab, an immunotherapy, is now in mainstream oncology practice given that it has shown improved overall survival in randomized clinical trials. Other immune modulating agents, such as programmed death receptor-1 and programmed death receptor ligand-1 antibodies, are showing promise in early clinical trials. This manuscript will review ipilimumab and its most common side effects. Immune-related adverse events (irAEs) are important to recognize early, and their presentation, timing of onset, and general recommendations for workup and management will be reviewed. Assembling a multidisciplinary team, as well as thorough education of the patient, is recommended to optimize patient care. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 191 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 1% |
| United Kingdom | 1 | <1% |
| Netherlands | 1 | <1% |
| France | 1 | <1% |
| Unknown | 186 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 28 | 15% |
| Researcher | 26 | 14% |
| Student > Master | 25 | 13% |
| Student > Ph. D. Student | 22 | 12% |
| Other | 19 | 10% |
| Other | 28 | 15% |
| Unknown | 43 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 70 | 37% |
| Agricultural and Biological Sciences | 19 | 10% |
| Biochemistry, Genetics and Molecular Biology | 16 | 8% |
| Nursing and Health Professions | 10 | 5% |
| Immunology and Microbiology | 10 | 5% |
| Other | 20 | 10% |
| Unknown | 46 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2023.
All research outputs
#2,762,419
of 25,394,764 outputs
Outputs from Oncologist
#643
of 3,985 outputs
Outputs of similar age
#23,141
of 209,486 outputs
Outputs of similar age from Oncologist
#7
of 39 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,985 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.0. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,486 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.